Boston Scientific Taxus Japan Launch Delayed Until Second Half Of 2006
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific will begin a required Japanese premarket approval trial next year for its Taxus paclitaxel-eluting stent, incorporating a short-term endpoint of major adverse coronary events (MACE)